Table 3 Summary of previous studies on stereotactic body radiotherapy boost after external beam radiotherapy
Author (Y) | Design | No. | Risk group (%) | EBRT (Gy/fx) | WPRT rate | Boost modality (%) | Boost (Gy/fx) | Administration of ADT/duration (M) | Median f/u (M) | Late toxicities | BCRFS |
|---|---|---|---|---|---|---|---|---|---|---|---|
Pasquier (2020) [12] | P | 76 | I (100) | 46/23 | None | CK (79) Gantry-based (21) | 18/3 | None | 62 | 5Y cumulative incidence G ≥ 2: 1.4% (GU), 9.3% (GI) | 5Y 87.4% |
Joseph (2019) [17] | P | 237 | I (14) | 46/23 | None | HDRB (100) | 19.5/3 | 48%/6 | 126a | Absolute 1.3% of SAE | 10Y LRFSa 97.8% |
H (86) | 52%/18 | ||||||||||
7.4Y urethral stricture: 12.7% | |||||||||||
Pryor (2019) [18] | P | 135 | I (76) | 46/23 | 8% | Gantry-based (100) | 19 or 20/2 | 36%/ ≤6 | 24 | 2Y cumulative incidence G ≥ 2: 24.9% (GU), 4.5% (GI) | 2Y 98.6% |
H (24) | 18%/> 6 | Two G3 (GU), one G3 (GI) | |||||||||
Kim (2017) [11] | R | 39 | I (51) | 45/25 | 100% | CK (100) | 21/3 | None | 54 | G2 10.3% (GU), 12.8% (GI) | 5Y 94.7% |
H (49) | No G ≥ 3 | ||||||||||
Mercado (2016) [7] | R | 108 | L (4) | 45–50.4/25–28 | None | CK (100) | 19.5/3 | 64%/median 6 M | 53 | 2Y cumulative incidence (moderate to big by EPIC): 13.7% (GU), 5% (GI) | 3Y 100%(I), 89.8%(H) |
I (42) | |||||||||||
H (54), | |||||||||||
Anwar (2016) [9] | P | 48 | I (29) | 45/25 | 100% | CK (100) | 19 or 21/2 | 88%/median 6 M | 43 | G2 27% (GU), None (GI) | 5Y 90% |
H (71) | One G3 case | ||||||||||
Lin (2014) [10] | R | 41 | H (100) | 45/25 | 100% | CK (100) | 21/3 | 100%/long-term | 42 | G2 3–11% (GU), None (GI) | 4Y 91.9% |
No G ≥ 3 | |||||||||||
Katz (2014) [8] | R | 45 | H (100) | 45/25 | 100% | CK (100) | 18–21/3 | 62%/NA | 69 | GU: G2 2.3%, G3 2.3% | 6Y 69% |
GI: G2 13.3%, No G3 | |||||||||||
Present | P | 26 | H (100) | 44/20 | 100% | CK (100) | 18 or 21/3 | 100%/median 25 M | 35 | No G ≥ 2 (GU), G2 4% (GI) | 3Y 88.1% |